News & Updates
Filter by Specialty:
Statins show therapeutic potential in COVID-19-related acute kidney injury
COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.
Statins show therapeutic potential in COVID-19-related acute kidney injury
26 Oct 2022Tenofovir alafenamide reduces liver stiffness in CHB patients
Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.
Tenofovir alafenamide reduces liver stiffness in CHB patients
26 Oct 2022Smell, taste dysfunction post-COVID-19: will these persist?
Olfactory and gustatory** loss/alterations are common COVID-19 symptoms, but recovery is expected in most patients within the first 3 months. However, these dysfunctions may persist in some individuals, according to a reconstructed meta-analysis from Singapore.
Smell, taste dysfunction post-COVID-19: will these persist?
26 Oct 2022Cefepime-taniborbactam trumps meropenem for complicated UTI
Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.
Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
23 Oct 2022Circulating T cells tied to CVD risk in people with HIV infection
Subsets of peripheral circulating CD4 T cell among people with HIV infection (PWH) are predictive of incident cardiovascular disease (CVD), including heart failure and atherosclerotic CVD, reveals a study.
Circulating T cells tied to CVD risk in people with HIV infection
20 Oct 2022Beta-blocker shows potential for diabetic foot ulcers
A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).